On the 23rd, Yuhan Corporation (CEO, Wook-Je Cho) announced on the 23rd that it has been listed as the second largest shareholder by adding 10 billion won to April Bio, which has Serum Albumin Fragment Associated (SAFA) technology.
April Bio is a new antibody drug company that develops global innovative drugs in various therapeutic areas using its own human antibody library (HuDVFab) technology and SAFA (Serum Albumin Fragment Associated), a sustained platform technology that can increase the half-life of antibody fragment utilization. .
April Bio is preparing for phase 1 clinical trial in the United States this year, APB-A1, a preclinical inflammatory autoimmune disease drug (IL-18 target), APB-R3, male infertility treatment (FSH target) APB -R2, etc. are being developed.
Recently, April Bio decided to increase the amount of 10 billion won by third-party allocation to Yuhan Corporation, and attracted 18 billion won in Series B investment in 2020, and Yuhan Corporation also made 3 billion won to April Bio as a strategic investor (SI). It has invested and acquired a 4.89% stake.
In particular, the excellence of the SAFA (Serum Albumin Fragment Associated), an independent platform technology owned by April Bio, was recognized for the additional investment made by Yuhan Corporation, an existing strategic investor (SI), and announced plans to further accelerate joint research using this in the future. .
Meanwhile, April Bio is preparing for a special listing on the KOSDAQ market this year through technology evaluation, and major financial investors are LB Investment, TS Investment, Hana Financial Investment, Ebest Investment & Securities, SJ Investment Partners, Daekyo Investment, Mirae Equity Partners, These include SM Cino Technology Investment, BSK Investment, Wooshin Venture Investment, and Kolon Investment.
Copyright © Pax Economic TV Unauthorized reproduction and redistribution prohibited